WINSHIP4236-17: Evaluation of Human Immune Responses to Vaccination in Patients with Lymphoma

WINSHIP4236-17: Evaluation of Human Immune Responses to Vaccination in Patients with Lymphoma

Gender
Minimum Age
Maximum Age
Adults
Physicians
Chang, Andres
Phases
N/A
Drugs
N/A
Disease Sites
Non-Hodgkin's Lymphoma
Locations
Winship Cancer Institute of Emory University
NCT ID
NCT03501576
Protocol Number
WINSHIP4236-17
Contact
If interested in learning more about this clinical trial, please contact winshipcto@emory.edu or (404) 778-1868.

Title

WINSHIP4236-17: Evaluation of Human Immune Responses to Vaccination in Patients with Lymphoma

Summary

Primary Objective:

-To determine the seroprotection and seroconversion rate after influenza vaccination in patients with lymphoma receiving active treatment

Secondary Objectives:

-To characterize influenza-specific plasmablasts and memory B cells after influenza vaccination in patients with lymphoma receiving active treatment

-To investigate the longevity of humoral immunity to influenza virus in patients with lymphoma receiving active treatment

-To assess the timing and strength of the peak immune response to influenza vaccination

-To assess the effect of different lymphomas and treatment modalities in the immune response to influenza vaccination

Detail

Primary Objective:

-To determine the seroprotection and seroconversion rate after influenza vaccination in patients with lymphoma receiving active treatment

Secondary Objectives:

-To characterize influenza-specific plasmablasts and memory B cells after influenza vaccination in patients with lymphoma receiving active treatment

-To investigate the longevity of humoral immunity to influenza virus in patients with lymphoma receiving active treatment

-To assess the timing and strength of the peak immune response to influenza vaccination

-To assess the effect of different lymphomas and treatment modalities in the immune response to influenza vaccination

Eligibility